Viatris (VTRS)

• Market cap: $9.32B
• 1 day: 1.56%
• 5 days: 3.72%
• 1 month: -16.02%
• 3 months: -29.89%
• 6 months: -32.38%
• Year to date: -37.12%
• 1 year: -31.25%
• 5 years: -49.74%
• 10 years: -49.74%
• Sector: Healthcare
• Industry: Drug Manufacturers - Specialty & Generic

About: Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.

Employees: 32,000

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

44% more first-time investments, than exits

New positions opened: 140 | Existing positions closed: 97

17% more funds holding in top 10

Funds holding in top 10: 12 [Q3] → 14 (+2) [Q4]

13% more capital invested

Capital invested by funds: $10.9B [Q3] → $12.4B (+$1.47B) [Q4]

4.55% more ownership

Funds ownership: 78.82% [Q3] → 83.37% (+4.55%) [Q4]

3% more funds holding

Funds holding: 984 [Q3] → 1,009 (+25) [Q4]

0% more call options, than puts

Call options by funds: $35M | Put options by funds: $34.9M

18% less repeat investments, than reductions

Existing positions increased: 306 | Existing positions reduced: 374

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $9 15% upside
• Avg. target: $10.50 34% upside
• High target: $13 66% upside

4 analyst ratings

• positive: 1 25%
• neutral: 1 25%
• negative: 2 50%

Jefferies Glen Santangelo 45% 1-year accuracy 5 / 11 met price target	66% upside $13	Buy Maintained	7 Mar 2025
Piper Sandler David Amsellem 39% 1-year accuracy 13 / 33 met price target	28% upside $10	Neutral Reiterated	5 Mar 2025
Barclays Balaji Prasad 19% 1-year accuracy 8 / 43 met price target	15% upside $9	Underweight Maintained	28 Feb 2025
B of A Securities Jason Gerberry 21% 1-year accuracy 4 / 19 met price target	28% upside $10	Underperform Maintained	28 Feb 2025